PILL's Underlying Holdings Could Mean 33% Gain Potential
ETF Channel Staff - Thursday, May 27, 7:59 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily Pharmaceutical & Medical Bull 3X Shares
ETF (PILL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $28.77 per unit.
With PILL trading at a recent price near $21.69 per unit, that means that analysts see 32.66% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of PILL's underlying holdings with notable upside to their analyst target prices are Reata Pharmaceuticals Inc (RETA), Theravance Biopharma, Inc. (TBPH), and Cassava Sciences Inc (SAVA). Although RETA has traded at a recent price of $126.78/share, the average analyst target is 84.83% higher at $234.33/share. Similarly, TBPH has 83.84% upside from the recent share price of $16.50 if the average analyst target price of $30.33/share is reached, and analysts on average are expecting SAVA to reach a target price of $82.00/share, which is 61.10% above the recent price of $50.90. Below is a twelve month price history chart comparing the stock performance of RETA, TBPH, and SAVA:
Combined, RETA, TBPH, and SAVA represent 6.20% of the Daily Pharmaceutical & Medical Bull 3X Shares
ETF. Below is a summary table of the current analyst target prices discussed above:
|Name ||Symbol ||Recent Price ||Avg. Analyst 12-Mo. Target ||% Upside to Target|
|Daily Pharmaceutical & Medical Bull 3X Shares
ETF ||PILL ||$21.69 ||$28.77 ||32.66%|
|Reata Pharmaceuticals Inc ||RETA ||$126.78 ||$234.33 ||84.83%|
|Theravance Biopharma, Inc. ||TBPH ||$16.50 ||$30.33 ||83.84%|
|Cassava Sciences Inc ||SAVA ||$50.90 ||$82.00 ||61.10%|
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on RETA — FREE
Get the latest Zacks research report on TBPH — FREE
Get the latest Zacks research report on SAVA — FREE